Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell Therapy

[1]  Markel Vigo,et al.  Assessing the communication gap between AI models and healthcare professionals: explainability, utility and trust in AI-driven clinical decision-making , 2022, Artif. Intell..

[2]  Marcel van Gerven,et al.  Explainable Deep Learning: A Field Guide for the Uninitiated , 2020, J. Artif. Intell. Res..

[3]  W. Hersh,et al.  Clinical study applying machine learning to detect a rare disease: results and lessons learned , 2021, medRxiv.

[4]  G. Salles,et al.  Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.

[5]  Qihang Sun,et al.  Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies , 2021, Journal of Experimental & Clinical Cancer Research.

[6]  A. Cavalli,et al.  Opportunities and Challenges for Machine Learning in Rare Diseases , 2021, Frontiers in Medicine.

[7]  R. Houot,et al.  Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma , 2021, British journal of haematology.

[8]  A. Liang,et al.  Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis , 2021, Cancers.

[9]  R. Houot,et al.  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study , 2021, The Lancet.

[10]  M. Sadelain,et al.  Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy , 2021, Nature Reviews Immunology.

[11]  Erliang Zeng,et al.  Dataset-chemokines, cytokines, and biomarkers in the saliva of children with Sjögren's syndrome , 2021, Data in brief.

[12]  Jun-qing Xu,et al.  A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma , 2021, Translational oncology.

[13]  Hong Liu,et al.  Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment , 2021, Frontiers in Immunology.

[14]  Erliang Zeng,et al.  A distinguishing profile of chemokines, cytokines and biomarkers in the saliva of children with Sjögren’s syndrome , 2021, Rheumatology.

[15]  Hui Xiong,et al.  A Comprehensive Survey on Transfer Learning , 2019, Proceedings of the IEEE.

[16]  He Huang,et al.  Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy , 2020, Bone Marrow Transplantation.

[17]  Bing Zhang,et al.  Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma , 2020, Cancer medicine.

[18]  S. Thun,et al.  The use of machine learning in rare diseases: a scoping review , 2020, Orphanet Journal of Rare Diseases.

[19]  M. Perales,et al.  Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. , 2020, Blood advances.

[20]  Alejandro Barredo Arrieta,et al.  Explainable Artificial Intelligence (XAI): Concepts, Taxonomies, Opportunities and Challenges toward Responsible AI , 2019, Inf. Fusion.

[21]  Junnian Zheng,et al.  A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. , 2019, The Lancet. Haematology.

[22]  Amit Dhurandhar,et al.  TED: Teaching AI to Explain its Decisions , 2018, AIES.

[23]  B. Lei,et al.  A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma , 2018, Journal of Hematology & Oncology.

[24]  Delong Liu,et al.  Cytokine release syndrome: grading, modeling, and new therapy , 2018, Journal of Hematology & Oncology.

[25]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[26]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[27]  Lalana Kagal,et al.  Explaining Explanations: An Overview of Interpretability of Machine Learning , 2018, 2018 IEEE 5th International Conference on Data Science and Advanced Analytics (DSAA).

[28]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[29]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[30]  Wojciech Samek,et al.  Methods for interpreting and understanding deep neural networks , 2017, Digit. Signal Process..

[31]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[32]  Daniel Li,et al.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.

[33]  D. Dimitrov,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature medicine.

[34]  J. Byrd,et al.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Scott Lundberg,et al.  A Unified Approach to Interpreting Model Predictions , 2017, NIPS.

[36]  Avanti Shrikumar,et al.  Learning Important Features Through Propagating Activation Differences , 2017, ICML.

[37]  H. Zhang,et al.  Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia , 2016, Clinical Cancer Research.

[38]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[39]  O. Oluwole,et al.  At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies , 2016, Journal of leukocyte biology.

[40]  G. Wertheim,et al.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.

[41]  Paolo Gastaldo,et al.  Inductive bias for semi-supervised extreme learning machine , 2016, Neurocomputing.

[42]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[43]  Eugenia G. Giannopoulou,et al.  Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation , 2015, Nature Immunology.

[44]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Ewout W Steyerberg,et al.  Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints , 2014, BMC Medical Research Methodology.

[46]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[47]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[48]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[49]  Yongmin Tang,et al.  Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. , 2014, Cancer letters.

[50]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[51]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[52]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[53]  Robert F. Stengel,et al.  Dynamics of a Cytokine Storm , 2012, PloS one.

[54]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[55]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[56]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[57]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Davide Anguita,et al.  Using Unsupervised Analysis to Constrain Generalization Bounds for Support Vector Classifiers , 2010, IEEE Transactions on Neural Networks.

[59]  I. Hozo,et al.  Estimating the mean and variance from the median, range, and the size of a sample , 2005, BMC medical research methodology.

[60]  Thomas G. Dietterich.  Multiple Classifier Systems , 2000, Lecture Notes in Computer Science.